Table 1.
Immunohistochemistry staining for patients with breast cancer.
| Case number | Diagnosis | Histology | ER | PR | HER2 | ADAM9 IHC intensity | ADAM9 staining percentage |
|---|---|---|---|---|---|---|---|
| 1 | TNBC, metastasis | IDC | / | / | / | 3+ | 70% |
| 2 | TNBC, metastasis | IDC | / | / | / | 1+ | 30% |
| 3 | TNBC, metastasis | IDC | / | / | / | 3+ | 40% |
| 4 | TNBC, metastasis | IDC | / | / | / | 3+ | 50% |
| 5 | TNBC, metastasis | IDC | / | / | / | 2+ | 40% |
| 6 | TNBC, metastasis | IDC | / | / | / | 1+ | 70% |
| 7 | TNBC, LN metastasis | IDC | / | / | / | 2+ | 20% |
| 8 | TNBC, LN metastasis | IDC | / | / | / | 2.5+ | 20% |
| 9 | TNBC, LN metastasis | IDC | / | / | / | 1+ | 60% |
| 10 | TNBC, LN metastasis | IDC | / | / | / | 3+ | 30% |
| 11 | TNBC, LN metastasis | IDC | / | / | / | 2+ | 10% |
| 12 | TNBC, LN metastasis | IDC | / | / | / | 3.5+ | 70% |
| 13 | TNBC, non-metastasis | IDC | / | / | / | 1+ | 20% |
| 14 | TNBC, non-metastasis | IDC | / | / | / | 2+ | 60% |
| 15 | TNBC, non-metastasis | IDC | / | / | / | 1+ | 10% |
| 16 | TNBC, non-metastasis | IDC | / | / | / | 3+ | 60% |
| 17 | TNBC, non-metastasis | IDC | / | / | / | 2.5+ | 30% |
| 18 | TNBC, non-metastasis | IDC | / | / | / | 4+ | 30% |
| 19 | TNBC, non-metastasis | IDC | / | / | / | 2+ | 40% |
| 20 | TNBC, non-metastasis | IDC | / | / | / | 2.5+ | 20% |
| 21 | TNBC, non-metastasis | IDC | / | / | / | 3+ | 60% |
| 22 | TNBC, non-metastasis | IDC | / | / | / | 3.5+ | 70% |
| 23 | TNBC, non-metastasis | IDC | / | / | / | 2.5+ | 10% |
| 24 | TNBC, non-metastasis | IDC | / | / | / | 3.5+ | 10% |
| 25 | Non-TNBC | IDC | 6 | 8 | 0 | 1+ | 50% |
| 26 | Non-TNBC | IDC | 8 | 8 | 1 | 0.5+ | 10% |
| 27 | Non-TNBC | IDC | 7 | 5 | 2 | 2+ | 20% |
| 28 | Non-TNBC | IDC | 8 | 8 | 2 | 1+ | 70% |
| 29 | Non-TNBC | IDC | 7 | 0 | 3 | 1+ | 70% |
| 30 | Non-TNBC | IDC | 7 | 6 | 2 | 0.5+ | 10% |
| 31 | Non-TNBC | IDC | 8 | 8 | 2 | 2+ | 25% |
| 32 | Non-TNBC | IDC | 8 | 5 | 2 | 2+ | 10% |
| 33 | Non-TNBC | IDC | 8 | 8 | 1 | 0.5+ | 40% |
| 34 | Non-TNBC | IDC | 8 | 8 | 0 | 0.5+ | 50% |
| 35 | Non-TNBC | IDC | 8 | 6 | 1 | 2+ | 30% |
| 36 | Non-TNBC | IDC | 8 | 7 | 2 | 2+ | 40% |
| 37 | Non-TNBC | IDC | 8 | 8 | 0 | 3+ | 40% |
| 38 | Non-TNBC | IDC | 8 | 8 | 2 | 3+ | 60% |
| 39 | Non-TNBC | IDC | 6 | 8 | 1 | 2.5+ | 40% |
| 40 | Non-TNBC | IDC | 8 | 8 | 2 | 2+ | 50% |
| 41 | Non-TNBC | IDC | 8 | 0 | 2 | 2+ | 10% |
| 42 | Non-TNBC | IDC | 8 | 0 | 2 | 3+ | 10% |
| 43 | Non-TNBC | IDC | 8 | 7 | 3 | 2+ | 40% |
| 44 | Non-TNBC | IDC | 8 | 7 | 2 | 2+ | 10% |
LN, lymph node; IDC, invasive ductal carcinoma; IHC, immunohistochemistry; TNBC, triple-negative breast cancer.